Shenkang injection combined with alprostadil for chronic renal failure: A systematic review and meta-analysis

Objective: To systematically evaluate the clinical e similar to cacy and safety of Shenkang injection (SKI) combined with alprostadil in the treatment of chronic renal failure (CRF). Method: Randomized controlled trials (RCTs) of Shenkang injection combined with alprostadil in CRF treatment were investigated by retrieving a total of 7 databases including CNKI, Wanfang database, VIP, CBM, PubMed, Embase and Cochrane Library, with the search time ranging from 2012 to now. Revman 5.2 software was used for data analysis, and Cochrane bias risk tool was used to evaluate the quality of the included literature. The final results were represented by relative risk (RR), mean di erence (MD) and 95% confidence interval (95% CI). Results: A total of 20 RCTs and 1,573 patients were included in this study. Metaanalysis showed that the overall response rate (ORR) of the treatment group was superior to the control group [RR = 0.20, 95% CI (0.16, 0.25), P < 0.00001]. Compared with the control group, the treatment group achieved favorable improvement in terms of the creatinine clearance rate (Ccr) [MD = 9.48, 95% CI (8.73, 10.24), P < 0.00001], serum creatinine (Scr) [MD = -55.12, 95% CI (-63.42, -46.82), P < 0.00001], quantitative urine protein (Upro) [MD = -0.48, 95% CI (-0.53, -0.43), P < 0.00001], and blood urea nitrogen (BUN) [MD=-3.73, 95% CI (-4.08, -3.3) 7, P < 0.00001]. There was no statistical di erence in the incidence of adverse reactions in each group. Conclusion: Currently, Shenkang injection combined with alprostadil has been widely used in clinical treatment of CRF due to the certain e ect superior to othermethods. However, its specific e similar to cacy and safety need to be further verified through numerous large-scale clinical trials.

Automated summary

The objective of this study was to evaluate the clinical efficacy and safety of Shenkang injection combined with alprostadil in treating chronic renal failure. The results showed that the treatment group had a higher overall response rate compared to the control group, and also showed significant improvements in creatinine clearance rate, serum creatinine, quantitative urine protein, and blood urea nitrogen. There was no statistical difference in the incidence of adverse reactions between the two groups. Further large-scale clinical trials are needed to verify its specific efficacy and safety.